

# Prevention of radiotherapy side-effects by early hyperbaric oxygen administration

<b>Submission date</b> 04/04/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/04/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/09/2008	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof P.C. Levendag

**Contact details**  
Erasmus Medical Centre  
Department of Radiotherapy  
Groenehilledijk 301  
Rotterdam  
Netherlands  
3075 EA  
p.levendag@erasmusmc.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
MEC 2005-318; NTR617

# Study information

## Scientific Title

## Study objectives

To prevent radiotherapy side-effects with early hyperbaric oxygen administration.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethics approval received from the local medical ethics committee

## Study design

Randomised, active controlled, parallel group trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Nasopharyngeal cancer, oropharyngeal cancer

## Interventions

Randomisation of hyperbaric oxygen (one group with and one group without). Treatment consists of 30 sessions of 2 hours a day.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

1. Xerostomia
2. Mucositis
3. Trismus

## Secondary outcome measures

1. Tumour control
2. Quality of life

**Overall study start date**

06/02/2006

**Completion date**

06/02/2009

## Eligibility

**Key inclusion criteria**

1. Curative intent
2. Presence of oropharynx and nasopharynx tumours

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

180

**Key exclusion criteria**

Palliative treatment

**Date of first enrolment**

06/02/2006

**Date of final enrolment**

06/02/2009

## Locations

**Countries of recruitment**

Netherlands

**Study participating centre**

Erasmus Medical Centre

Rotterdam

Netherlands

3075 EA

# Sponsor information

## Organisation

Erasmus Medical Centre (The Netherlands)

## Sponsor details

P.O. Box 2040

Rotterdam

Netherlands

3000 CA

## Sponsor type

Hospital/treatment centre

## ROR

<https://ror.org/018906e22>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Erasmus Medical Centre (The Netherlands)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration